101
|
Cissé M, Duplan E, Guillot-Sestier MV, Rumigny J, Bauer C, Pagès G, Orzechowski HD, Slack BE, Checler F, Vincent B. The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein. J Biol Chem 2011; 286:29192-29206. [PMID: 21586567 DOI: 10.1074/jbc.m110.208249] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The α-secretases A disintegrin and metalloprotease 10 (ADAM10) and ADAM17 trigger constitutive and regulated processing of the cellular prion protein (PrP(c)) yielding N1 fragment. The latter depends on protein kinase C (PKC)-coupled M1/M3 muscarinic receptor activation and subsequent phosphorylation of ADAM17 on its intracytoplasmic threonine 735. Here we show that regulated PrP(c) processing and ADAM17 phosphorylation and activation are controlled by the extracellular-regulated kinase-1/MAP-ERK kinase (ERK1/MEK) cascade. Thus, reductions of ERK1 or MEK activities by dominant-negative analogs, pharmacological inhibition, or genetic ablation all impair N1 secretion, whereas constitutively active proteins increase N1 recovery in the conditioned medium. Interestingly, we also observed an ERK1-mediated enhanced expression of PrP(c). We demonstrate that the ERK1-associated increase in PrP(c) promoter transactivation and mRNA levels involve transcription factor AP-1 as a downstream effector. Altogether, our data identify ERK1 as an important regulator of PrP(c) cellular homeostasis and indicate that this kinase exerts a dual control of PrP(c) levels through transcriptional and post-transcriptional mechanisms.
Collapse
Affiliation(s)
- Moustapha Cissé
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Eric Duplan
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Marie-Victoire Guillot-Sestier
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Joaquim Rumigny
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Charlotte Bauer
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France
| | - Gilles Pagès
- Institute of Developmental Biology and Cancer, Unité Mixte de Recherche, 6543 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Centre Antoine Lacassagne, 06189 Nice, France
| | - Hans-Dieter Orzechowski
- Institute of Clinical Pharmacology and Toxicology, Charité-Universitaetsmedizin Berlin, Campus Mitte, Luisenstrasse 10-11, 10117 Berlin, Germany, and
| | - Barbara E Slack
- Boston University School of Medicine, Boston, Massachusetts 02118
| | - Frédéric Checler
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France,.
| | - Bruno Vincent
- Institut de Pharmacologie Moléculaire et Cellulaire and Institut de Neuro-Médecine Moléculaire, Unité Mixte de Recherche, 6097 Centre National de la Recherche Scientifique/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des lucioles, Sophia-Antipolis, 06560 Valbonne, France,.
| |
Collapse
|
102
|
Sakudo A, Onodera T. Tissue- and cell type-specific modification of prion protein (PrP)-like protein Doppel, which affects PrP endoproteolysis. Biochem Biophys Res Commun 2011; 404:523-7. [DOI: 10.1016/j.bbrc.2010.12.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Accepted: 12/02/2010] [Indexed: 10/18/2022]
|
103
|
Metalloproteases and Proteolytic Processing. POST-TRANSLATIONAL MODIFICATIONS IN HEALTH AND DISEASE 2011. [PMCID: PMC7120770 DOI: 10.1007/978-1-4419-6382-6_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Proteolytic enzymes constitute around 2% of the human genome and are involved in all stages of cell and organism development from fertilization through to cell death. In the human genome the major classes of peptidases are represented by cysteine-, serine- and metalloenzymes, which possess a wide spectrum of substrate specificity and physiological functions. The identification of many novel peptidases from genome sequencing programmes has suggested potential new therapeutic targets. In addition, several well characterised peptidases were recently shown to possess new and unexpected biological roles in neuroinflammation, cancer and angiogenesis, cardiovascular diseases and neurodegeneration. This chapter will briefly characterize the main classes of metallopeptidases and their roles in health and disease. Particular attention will be paid to the angiotensin-converting enzyme (ACE), neprilysin (NEP) and adamalysin (ADAM) families of proteases and their pathophysiological roles with a particular emphasis on cancer and neurodegeneration. The roles and mechanisms of protein shedding which primarily involve the ADAMs family of metallopeptidases will be explained using amyloid protein precursor (APP) processing cascades as a well characterized example. The therapeutic significance of modulating (activating or inhibiting) metallopeptidase activity will be a particular focus of this chapter.
Collapse
|
104
|
Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol Aging 2010; 32:556.e13-23. [PMID: 21196064 DOI: 10.1016/j.neurobiolaging.2010.10.020] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Revised: 10/27/2010] [Accepted: 10/28/2010] [Indexed: 12/22/2022]
Abstract
The aim of this exploratory investigation was to determine if genetic variation within amyloid precursor protein (APP) or its processing enzymes correlates with APP cleavage product levels: APPα, APPβ or Aβ42, in cerebrospinal fluid (CSF) of cognitively normal subjects or Alzheimer's disease (AD) patients. Cognitively normal control subjects (n = 170) and AD patients (n = 92) were genotyped for 19 putative regulatory tagging SNPs within 9 genes (APP, ADAM10, BACE1, BACE2, PSEN1, PSEN2, PEN2, NCSTN and APH1B) involved in the APP processing pathway. SNP genotypes were tested for their association with CSF APPα, APPβ, and Aβ42, AD risk and age-at-onset while taking into account age, gender, race and APOE ε4. After adjusting for multiple comparisons, a significant association was found between ADAM10 SNP rs514049 and APPα levels. In controls, the rs514049 CC genotype had higher APPα levels than the CA, AA collapsed genotype, whereas the opposite effect was seen in AD patients. These results suggest that genetic variation within ADAM10, an APP processing gene, influences CSF APPα levels in an AD specific manner.
Collapse
Affiliation(s)
- L M Bekris
- Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, WA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
105
|
Ectodomain shedding of the Notch ligand Jagged1 is mediated by ADAM17, but is not a lipid-raft-associated event. Biochem J 2010; 432:283-94. [PMID: 20819075 DOI: 10.1042/bj20100321] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Notch signalling is an evolutionarily conserved pathway involved in cell-fate specification. The initiating event in this pathway is the binding of a Notch receptor to a DSL (Delta/Serrate/Lag-2) ligand on neighbouring cells triggering the proteolytic cleavage of Notch within its extracellular juxtamembrane region; a process known as proteolytic 'shedding' and catalysed by members of the ADAM (a disintegrin and metalloproteinase) family of enzymes. Jagged1 is a Notch-binding DSL ligand which is also shed by an ADAM-like activity raising the possibility of bi-directional cell-cell Notch signalling. In the present study we have unequivocally identified the sheddase responsible for shedding Jagged1 as ADAM17, the activity of which has previously been shown to be localized within specialized microdomains of the cell membrane known as 'lipid rafts'. However, we have shown that replacing the transmembrane and cytosolic regions of Jagged1 with a GPI (glycosylphosphatidylinositol) anchor, thereby targeting the protein to lipid rafts, did not enhance its shedding. Furthermore, the Jagged1 holoprotein, its ADAM-cleaved C-terminal fragment and ADAM17 were not enriched in raft preparations devoid of contaminating non-raft proteins. We have also demonstrated that wild-type Jagged1 and a truncated polypeptide-anchored variant lacking the cytosolic domain were subject to similar constitutive and phorbol ester-regulated shedding. Collectively these data demonstrate that Jagged1 is shed by ADAM17 in a lipid-raft-independent manner, and that the cytosolic domain of the former protein is not a pre-requisite for either constitutive or regulated shedding.
Collapse
|
106
|
Lichtenthaler SF. α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J Neurochem 2010; 116:10-21. [PMID: 21044078 DOI: 10.1111/j.1471-4159.2010.07081.x] [Citation(s) in RCA: 133] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Ectodomain shedding of the amyloid precursor protein (APP) by the metalloprotease activity α-secretase is a key regulatory event preventing the generation of the Alzheimer's disease (AD) amyloid β peptide. Proteases similar to α-secretase are essential for diverse physiological processes, such as embryonic development, cell adhesion and neuronal guidance. Previously, several proteases were suggested as candidate α-secretases for APP, in particular members of the ADAM family (a disintegrin and metalloprotease). Two recent studies analyzed primary neurons, which are the cell type affected in AD, and finally demonstrated that the constitutively cleaving α-secretase activity is selectively mediated by ADAM10. An increase in α-secretase cleavage is considered a therapeutic approach for AD. However, the molecular mechanisms regulating α-secretase cleavage remain only partly understood. Signaling pathways activating protein kinase C and MAP kinase play a central role in stimulating α-secretase cleavage of APP. Additionally, several recent publications demonstrate that ADAM10 expression and α-secretase cleavage of APP are tightly controlled at the level of transcription, e.g. by retinoic acid receptors and sirtuins, and at the level of translation and protein trafficking. This review focuses on the recent progress made in unraveling the molecular identity, regulation and therapeutic potential of α-secretase in Alzheimer's disease.
Collapse
|
107
|
Gough M, Parr-Sturgess C, Parkin E. Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease. Biochem Res Int 2010; 2011:721463. [PMID: 21152187 PMCID: PMC2989646 DOI: 10.1155/2011/721463] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2010] [Accepted: 09/07/2010] [Indexed: 12/12/2022] Open
Abstract
Alzheimer's disease is a neurodegenerative condition characterized by an accumulation of toxic amyloid beta- (Aβ-)peptides in the brain causing progressive neuronal death. Aβ-peptides are produced by aspartyl proteinase-mediated cleavage of the larger amyloid precursor protein (APP). In contrast to this detrimental "amyloidogenic" form of proteolysis, a range of zinc metalloproteinases can process APP via an alternative "nonamyloidogenic" pathway in which the protein is cleaved within its Aβ region thereby precluding the formation of intact Aβ-peptides. In addition, other members of the zinc metalloproteinase family can degrade preformed Aβ-peptides. As such, the zinc metalloproteinases, collectively, are key to downregulating Aβ generation and enhancing its degradation. It is the role of zinc metalloproteinases in this "positive side of proteolysis in Alzheimer's disease" that is discussed in the current paper.
Collapse
Affiliation(s)
- Mallory Gough
- Division of Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
| | - Catherine Parr-Sturgess
- Division of Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
| | - Edward Parkin
- Division of Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
| |
Collapse
|
108
|
ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010; 29:3020-32. [PMID: 20676056 DOI: 10.1038/emboj.2010.167] [Citation(s) in RCA: 455] [Impact Index Per Article: 32.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2009] [Accepted: 06/28/2010] [Indexed: 12/28/2022] Open
Abstract
The amyloid precursor protein (APP) undergoes constitutive shedding by a protease activity called alpha-secretase. This is considered an important mechanism preventing the generation of the Alzheimer's disease amyloid-beta peptide (Abeta). alpha-Secretase appears to be a metalloprotease of the ADAM family, but its identity remains to be established. Using a novel alpha-secretase-cleavage site-specific antibody, we found that RNAi-mediated knockdown of ADAM10, but surprisingly not of ADAM9 or 17, completely suppressed APP alpha-secretase cleavage in different cell lines and in primary murine neurons. Other proteases were not able to compensate for this loss of alpha-cleavage. This finding was further confirmed by mass-spectrometric detection of APP-cleavage fragments. Surprisingly, in different cell lines, the reduction of alpha-secretase cleavage was not paralleled by a corresponding increase in the Abeta-generating beta-secretase cleavage, revealing that both proteases do not always compete for APP as a substrate. Instead, our data suggest a novel pathway for APP processing, in which ADAM10 can partially compete with gamma-secretase for the cleavage of a C-terminal APP fragment generated by beta-secretase. We conclude that ADAM10 is the physiologically relevant, constitutive alpha-secretase of APP.
Collapse
|
109
|
Dagdanova A, Ilchenko S, Notari S, Yang Q, Obrenovich ME, Hatcher K, McAnulty P, Huang L, Zou W, Kong Q, Gambetti P, Chen SG. Characterization of the prion protein in human urine. J Biol Chem 2010; 285:30489-95. [PMID: 20670940 DOI: 10.1074/jbc.m110.161794] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The presence of the prion protein (PrP) in normal human urine is controversial and currently inconclusive. This issue has taken a special relevance because prion infectivity has been demonstrated in urine of animals carrying experimental or naturally occurring prion diseases, but the actual presence and tissue origin of the infectious prion have not been determined. We used immunoprecipitation, one- and two-dimensional electrophoresis, and mass spectrometry to prove definitely the presence of PrP in human urine and its post-translational modifications. We show that urinary PrP (uPrP) is truncated mainly at residue 112 but also at other residues up to 122. This truncation makes uPrP undetectable with some commonly used antibodies to PrP. uPrP is glycosylated and carries an anchor which, at variance with that of cellular PrP, lacks the inositol-associated phospholipid moiety, indicating that uPrP is probably shed from the cell surface. The detailed characterization of uPrP reported here definitely proves the presence of PrP in human urine and will help determine the origin of prion infectivity in urine.
Collapse
Affiliation(s)
- Ayuna Dagdanova
- Department of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
110
|
Lee YJ, Baskakov IV. Treatment with normal prion protein delays differentiation and helps to maintain high proliferation activity in human embryonic stem cells. J Neurochem 2010; 114:362-73. [PMID: 20089130 DOI: 10.1111/j.1471-4159.2010.06601.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The normal cellular form of prion protein (PrP(C)) has been shown to exhibit a diverse range of biological activities. Several recent studies highlighted potential involvement of PrP(C) in embryogenesis or in regulating stem cell self-renewal and proliferation. In the current study, we employed human embryonic stem cells (hESCs) for assessing the potential role of prion protein in early human development. Here, we showed that treatment of hESCs with full-length recombinant PrP folded into an alpha-helical conformation similar to that of PrP(C) delayed the spontaneous differentiation of hESCs and helped to maintain their high proliferation activity during spontaneous differentiation. Considering that administration of alpha-rPrP was also found to down-regulate the expression of endogenous PrP(C), the effects of alpha-rPrP were likely to be indirect, i.e. executed by endogenous PrP(C). Together with previous observations, these work support the hypothesis that PrP(C) is involved in regulating self-renewal/differentiation status of stem cells including hESCs.
Collapse
Affiliation(s)
- Young Jin Lee
- Medical Biotechnology Center, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
| | | |
Collapse
|
111
|
Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. Brain Res 2009; 1296:203-15. [DOI: 10.1016/j.brainres.2009.07.105] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2009] [Revised: 07/30/2009] [Accepted: 07/30/2009] [Indexed: 11/18/2022]
|